Association of survivin splice variants with prognosis and treatment of breast cancer

World Journal of Clinical Oncology

Volumn 5, Issue 5, 2014, Pages 883-894

  Pavlidou, Anastasia ^a   Kroupis, Christos ^a   Dimas, Kleanthi ^a  

^a Attikon University General Hospital   (Greece)

Author keywords

Breast cancer; Isoforms; Prognosis; Survivin gene; Therapy

Indexed keywords

EID: 84931079235     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v5.i5.883     Document Type: Article

References (59)

1. Ferlay J, Shin HR, Bray F. GLOBOCAN 2008 v2.0, cancer incidence and mortality worldwide: IARC CancerBase no. 10 [internet]. Lyon, France: International Agency for Research on Cancer, 2010. Available from: URL: http: //globocan. iarc.fr. Accessed: June 5, 2013.
2. Poumpouridou N, Kroupis C. Hereditary breast cancer: beyond BRCA genetic analysis; PALB2 emerges. Clin Chem Lab Med 2012; 50: 423-434 [PMID: 22505525 DOI: 10.1515/cclm-2011-0840]
3. Shuen AY, Foulkes WD. Inherited mutations in breast cancer genes-risk and response. J Mammary Gland Biol Neoplasia 2011; 16: 3-15 [PMID: 21461995 DOI: 10.1007/s10911-011-9213-5]
4. Pavlidou A, Kroupis C, Goutas N, Dalamaga M, Dimas K. Validation of a real-time quantitative polymerase chain reaction method for the quantification of 3 survivin transcripts and evaluation in breast cancer tissues. Clin Breast Cancer 2014; 14: 122-131 [PMID: 24325949 DOI: 10.1016/j.clbc.2013.10.012]
5. Pavlidou A, Dalamaga M, Kroupis C, Konstantoudakis G, Belimezi M, Athanasas G, Dimas K. Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR. World J Gastroenterol 2011; 17: 1614-1621 [PMID: 21472129 DOI: 10.3748/wjg.v17.i12]
6. Nestal de Moraes G, Vasconcelos FC, Delbue D, Mognol GP, Sternberg C, Viola JP, Maia RC. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels. Eur J Cell Biol 2013; 92: 247-256 [PMID: 24064045 DOI: 10.1016/j.ejcb.2013.08.001]
7. Knauer SK, Bier C, Schlag P, Fritzmann J, Dietmaier W, Rödel F, Klein-Hitpass L, Kovács AF, Döring C, Hansmann ML, Hofmann WK, Kunkel M, Brochhausen C, Engels K, Lippert BM, Mann W, Stauber RH. The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle 2007; 6: 1502-1509 [PMID: 17582222]
8. Roca H, Varsos Z, Pienta KJ. CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation. J Biol Chem 2008; 283: 25057-25073 [PMID: 18611860 DOI: 10.1074/jbc.M801073200)]
9. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008; 14: 5000-5005 [PMID: 18698017]
10. Ryan B, O'Donovan N, Browne B, O'Shea C, Crown J, Hill AD, McDermott E, O'Higgins N, Duffy MJ. Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Br J Cancer 2005; 92: 120-124 [PMID: 15611790]
11. Xie D, Zeng YX, Wang HJ, Wen JM, Tao Y, Sham JS, Guan XY. Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma. Br J Cancer 2006; 94: 108-114 [PMID: 16404364]
12. Virrey JJ, Guan S, Li W, Schönthal AH, Chen TC, Hofman FM. Increased survivin expression confers chemoresistance to tumor-associated endothelial cells. Am J Pathol 2008; 173: 575-585 [PMID: 18599610]
13. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Tenjo T, Tanigawa N. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 2001; 91: 2026-2032 [PMID: 11391581]
14. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11: 55-65 [PMID: 20005174]
15. Kittaneh M, Montero AJ, Glück S. Molecular profiling for breast cancer: a comprehensive review. Biomark Cancer 2013; 5: 61-70 [PMID: 24250234]
16. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB. Alternative isoform regulation in human tissue transcriptomes. Nature 2008; 456: 470-476 [PMID: 18978772 DOI: 10.1038/nature07509]
17. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, Sato Y, Sato-Otsubo A, Kon A, Nagasaki M, Chalkidis G, Suzuki Y, Shiosaka M, Kawahata R, Yamaguchi T, Otsu M, Obara N, Sakata-Yanagimoto M, Ishiyama K, Mori H, Nolte F, Hofmann WK, Miyawaki S, Sugano S, Haferlach C, Koeffler HP, Shih LY, Haferlach T, Chiba S, Nakauchi H, Miyano S, Ogawa S. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64-69 [PMID: 21909114 DOI: 10.1038/nature10496]
18. Moore MJ, Wang Q, Kennedy CJ, Silver PA. An alternative splicing network links cell-cycle control to apoptosis. Cell 2010; 142: 625-636 [PMID: 20705336 DOI: 10.1016/j.cell.2010.07.019]
19. Miura K, Fujibuchi W, Unno M. Splice isoforms as therapeutic targets for colorectal cancer. Carcinogenesis 2012; 33: 2311-2319 [PMID: 23118106 DOI: 10.1093/carcin/bgs347]
20. Caldas H, Honsey LE, Altura RA. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 2005; 4: 11 [PMID: 15743529]
21. Zheng W, Ma X, Wei D, Wang T, Ma Y, Yang S. Molecular cloning and bioinformatics analysis of a novel spliced variant of survivin from human breast cancer cells. DNA Seq 2005; 16: 321-328 [PMID: 16329164]
22. Végran F, Boidot R, Bonnetain F, Cadouot M, Chevrier S, Lizard-Nacol S. Apoptosis gene signature of Survivin and its splice variant expression in breast carcinoma. Endocr Relat Cancer 2011; 18: 783-792 [PMID: 21878572 DOI: 10.1530/ERC-11-0105]
23. Span PN, Tjan-Heijnen VC, Heuvel JJ, de Kok JB, Foekens JA, Sweep FC. Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer? Clin Chem 2006; 52: 1693-1700 [PMID: 16873289]
24. Athanassiadou AM, Patsouris E, Tsipis A, Gonidi M, Athanassiadou P. The significance of Survivin and Nectin-4 expression in the prognosis of breast carcinoma. Folia Histochem Cytobiol 2011; 49: 26-33 [PMID: 21526486]
25. Bartlett JM, Thomas J, Ross DT, Seitz RS, Ring BZ, Beck RA, Pedersen HC, Munro A, Kunkler IH, Campbell FM, Jack W, Kerr GR, Johnstone L, Cameron DA, Chetty U. Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Res 2010; 12: R47 [PMID: 20615243 DOI: 10.1186/bcr2604]
26. Lavasani MA, Moinfar F. Molecular classification of breast carcinomas with particular emphasis on "basal-like" carcinoma: a critical review. J Biophotonics 2012; 5: 345-366 [PMID: 22232077 DOI: 10.1002/jbio.201100097]
27. van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008; 452: 564-570 [PMID: 18385730 DOI: 10.1038/nature06915]
28. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009 [PMID: 12490681]
29. Habel LA, Sakoda LC, Achacoso N, Ma XJ, Erlander MG, Sgroi DC, Fehrenbacher L, Greenberg D, Quesenberry CP. HOXB13: IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease. Breast Cancer Res 2013; 15: R24 [PMID: 23497539]
30. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, Bernard PS, Ellis MJ. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010; 16: 5222-5232 [PMID: 20837693 DOI: 10.1158/1078-0432. CCR-10-1282]
31. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826 [PMID: 15591335]
32. Stemmer SM, Klang SH, Ben-Baruch N, Geffen DB, Steiner M, Soussan-Gutman L, Merling S, Svedman C, Rizel S, Lieberman N. The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients. Breast Cancer Res Treat 2013; 140: 83-92 [PMID: 23801158 DOI: 10.1007/s10549-013-2603-1]
33. Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW, Davidson NE, Ingle JN, Perez EA, Wood WC, Sparano JA, Badve S. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 2013; 105: 701-710 [PMID: 23641039 DOI: 10.1093/jnci/djt067]
34. Groner B, Weiss A. Targeting survivin in cancer: novel drug development approaches. BioDrugs 2014; 28: 27-39 [PMID: 23955284]
35. Weiss A, Brill B, Borghouts C, Delis N, Mack L, Groner B. Survivin inhibition by an interacting recombinant peptide, derived from the human ferritin heavy chain, impedes tumor cell growth. J Cancer Res Clin Oncol 2012; 138: 1205-1220 [PMID: 22426960]
36. Manning BD. Challenges and opportunities in defining the essential cancer kinome. Sci Signal 2009; 2: pe15 [PMID: 19318621]
37. Deleavey GF, Damha MJ. Designing chemically modified oligonucleotides for targeted gene silencing. Chem Biol 2012; 19: 937-954 [PMID: 22921062 DOI: 10.1016/j.chembiol.2012.07.011]
38. Abdraboh ME, Gaur RL, Hollenbach AD, Sandquist D, Raj MH, Ouhtit A. Survivin is a novel target of CD44-promoted breast tumor invasion. Am J Pathol 2011; 179: 555-563 [PMID: 21718681 DOI: 10.1016/j.ajpath.2011.04.042]
39. Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 2010; 46: 298-311 [PMID: 19948396]
40. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-789 [PMID: 20885409]
41. Wang C, Zheng X, Shen C, Shi Y. MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res 2012; 31: 58 [PMID: 22713668 DOI: 10.1186/1756-9966-31-58]
42. Holloway MP, Altura RA. Targeting survivin's co-conspirators: do alternative methods of trapping survivin in the nucleus have potential in triple-negative breast cancer therapy? Future Oncol 2012; 8: 907-909 [PMID: 22894664]
43. Jha K, Shukla M, Pandey M. Survivin expression and targeting in breast cancer. Surg Oncol 2012; 21: 125-131 [PMID: 21334875 DOI: 10.1016/j.suronc.2011.01.001]
44. Friedrichs B, Siegel S, Andersen MH, Schmitz N, Zeis M. Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies. Leuk Lymphoma 2006; 47: 978-985 [PMID: 16840186 DOI: 10.1080/10428190500464062]
45. Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, thor Straten P, Andersen MH. Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther 2004; 3: 173-179 [PMID: 14726703]
46. Tabrizi MA, Bornstein GG, Klakamp SL, Drake A, Knight R, Roskos L. Translational strategies for development of monoclonal antibodies from discovery to the clinic. Drug Discov Today 2009; 14: 298-305 [PMID: 19152840 DOI: 10.1016/j.drudis.2008.12.008]
47. Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, Watanabe N. Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 2000; 91: 1204-1209 [PMID: 11092988]
48. Papanikolaou V, Iliopoulos D, Dimou I, Dubos S, Kappas C, Kitsiou-Tzeli S, Tsezou A. Survivin regulation by HER2 through NF-κB and c-myc in irradiated breast cancer cells. J Cell Mol Med 2011; 15: 1542-1550 [PMID: 20716114 DOI: 10.1111/j.1582-4934.2010.01149.x]
49. Bache M, Holzapfel D, Kappler M, Holzhausen HJ, Taubert H, Dunst J, Hänsgen G. Survivin protein expression and hypoxia in advanced cervical carcinoma of patients treated by radiotherapy. Gynecol Oncol 2007; 104: 139-144 [PMID: 16919715]
50. Capalbo G, Rödel C, Stauber RH, Knauer SK, Bache M, Kappler M, Rödel F. The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target. Strahlenther Onkol 2007; 183: 593-599 [PMID: 17960333]
51. Wang QP, Wang Y, Wang XD, Mo XM, Gu J, Lu ZY, Pan ZL, Zhu YX. Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-κB expression in MCF-7/5-FU cells. Int J Biochem Cell Biol 2013; 45: 2036-2044 [PMID: 23838170 DOI: 10.1016/j.biocel.2013.06.026]
52. Díaz R, González-Sancho JM, Soldevilla B, Silva J, García JM, García V, Peña C, Herrera M, Gómez I, Bonilla F, Domínguez G. Differential regulation of TP73 isoforms by 1α,25-dihydroxyvitamin D3 and survivin in human colon and breast carcinomas. Genes Chromosomes Cancer 2010; 49: 1135-1142 [PMID: 20842728 DOI: 10.1002/gcc.20821]
53. Park SH, Park SJ, Kim JO, Shin JH, Kim ES, Jo YK, Kim JS, Park SJ, Jin DH, Hwang JJ, Lee SJ, Jeong SY, Lee C, Kim I, Cho DH. Down-Regulation of Survivin by Nemadipine-A Sensitizes Cancer Cells to TRAIL-Induced Apoptosis. Biomol Ther (Seoul) 2013; 21: 29-34 [PMID: 24009855 DOI: 10.4062/biomolther.2012.088]
54. Tomicic MT, Kaina B. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors. Biochim Biophys Acta 2013; 1835: 11-27 [PMID: 23006513 DOI: 10.1016/j.bbcan.2012.09.002]
55. Yamanaka K, Nakata M, Kaneko N, Fushiki H, Kita A, Nakahara T, Koutoku H, Sasamata M. YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer. Int J Oncol 2011; 39: 569-575 [PMID: 21674125 DOI: 10.3892/ijo.2011.1077]
56. Kaneko N, Yamanaka K, Kita A, Tabata K, Akabane T, Mori M. Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells. Biol Pharm Bull 2013; 36: 1921-1927 [PMID: 24432379]
57. Boidot R, Vegran F, Lizard-Nacol S. Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy. Int J Mol Med 2009; 23: 285-291 [PMID: 19148555]
58. Zheng WY, Kang YY, Li LF, Xu YX, Ma XY. Levels of effectiveness of gene therapies targeting survivin and its splice variants in human breast cancer cells. Drug Discov Ther 2011; 5: 293-298 [PMID: 22466440]
59. McKenzie JA, Grossman D. Role of the apoptotic and mitotic regulator survivin in melanoma. Anticancer Res 2012; 32: 397-404 [PMID: 22287725]